Afrocentric Investment (JSE:ACT) Research & Development: R0 Mil (TTM As of Dec. 2025)


JSE:ACT Afrocentric Investment Corp Ltd JSE:ACT
52 GF Score
Price R0.79
GF Value R2.09
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Afrocentric Investment Research & Development?

Afrocentric Investment JSE:ACT 52 Research & Development is R0 Mil as of Dec. 2025. GuruFocus rates JSE:ACT with a GF Score™ of 52/100 and a GF Value™ of R2.09 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Afrocentric Investment's Research & Development for the six months ended in Dec. 2025 was R0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was R0 Mil.

Afrocentric Investment  (JSE:ACT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Afrocentric Investment Research & Development Related Terms

Afrocentric Investment Research & Development Historical Data

* Premium members only.

The historical data trend for Afrocentric Investment's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Afrocentric Investment Research & Development Chart

Afrocentric Investment Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Afrocentric Investment Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
JSE:ACT
52GF Score
Afrocentric Investment Corp Ltd JSE:ACT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Afrocentric Investment Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was R0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of R0 Mil mean?
Afrocentric Investment (JSE:ACT) has a Research & Development of R0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Afrocentric Investment and its competitors.
Is Afrocentric Investment's Research & Development too high?
Afrocentric Investment's current Research & Development is R0 Mil. Overall, Afrocentric Investment has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Afrocentric Investment's Research & Development compare to HCA and THC?
Afrocentric Investment's Research & Development of R0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Afrocentric Investment and its competitors. Afrocentric Investment's current Research & Development is R0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Afrocentric Investment stock overvalued right now?
Based on GuruFocus' analysis, Afrocentric Investment (JSE:ACT) is currently considered Possible Value Trap. The stock's GF Value™ is R2.09, compared to a current price of R0.79 — trading 62.2% below its estimated fair value. The current Research & Development is R0 Mil. Afrocentric Investment's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Afrocentric Investment (JSE:ACT), the current Research & Development is R0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Afrocentric Investment (JSE:ACT) Overvalued in 2026?

Based on GuruFocus' analysis, Afrocentric Investment stock appears to be undervalued. The current stock price of R0.79 is trading 62.2% below its estimated GF Value™ of R2.09. GuruFocus considers Afrocentric Investment to be Possible Value Trap.

Key valuation signals for JSE:ACT:

  • Research & Development: R0 Mil
  • GF Value™: R2.09 vs. price of R0.79 (62.2% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the JSE:ACT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Afrocentric Investment Business Description

Address 37 Conrad Road, Florida North, Roodepoort, ZAF, 1709
Afrocentric Investment Corp Ltd is an investment holding company providing specialised services and products to the public and private healthcare sectors. It focuses on making quality healthcare accessible and affordable to members and beneficiaries, with the principal objective of ensuring the delivery of efficient health management services and the distribution of quality products. Its business segments include Healthcare SA, comprising medical scheme administration and health risk management services; Healthcare Retail, comprising pharmaceutical sales and services; Healthcare Africa, comprising healthcare services outside South Africa in Namibia and Mauritius; and IT-related services predominantly within South Africa. It operates across South Africa, Botswana, Mauritius, and Namibia.
52GF Score

Get the complete analysis for JSE:ACT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R0.79
Price
R2.09
GF Value